<DOC>
	<DOCNO>NCT02796872</DOCNO>
	<brief_summary>This survey multicenter , double-blind , randomize , control , parallel-designed , prospective trial intend evaluate Bimuno GOS effect growth , tolerance , gut health , fecal flora immune function .</brief_summary>
	<brief_title>The Effect Feeding Infant Formula With Bimuno Galactooligosaccharide ( GOS )</brief_title>
	<detailed_description />
	<criteria>15 ± 3 day age randomization , inclusive ( day birth consider day 0 ) Singleton birth Gestational age 3742 week ( 36 week six day consider 36 week gestational age ) Birth weight 2500g 4000g Signed inform consent obtain infant 's participation survey Parent guardian infant agree enroll infant another interventional clinical research survey participate survey APGAR score 5 minute life &gt; 7 Consuming one source nutrition Formulafed infant : Infant consume infant formula sole source nutrition 7 consecutive day prior randomization Breastfed infant : Infant consume mother 's breast milk sole source nutrition 7 consecutive day prior registration Infant inborn malformation hereditary and/or chronic and/or inborn disease require hospital care superior 7 day Diseases jeopardize intrauterine growth Weight Visit 1 &lt; 95 % birth weight [ ( weight Visit 1÷birth weight ) x 100 &lt; 95 % ] Infant born mother suffer metabolic and/or chronic disease Infant acute infection gastroenteritis time randomization registration Infant consume supplemental food Evidence feed difficulty formula intolerance , vomit poor intake time randomization registration Infant immunocompromised ( accord doctor 's diagnosis immunodeficiency Combined Immunodeficiencies , DiGeorge Syndrome , WiskottAldrich Syndrome , Severe Congenital Neutropenia Secondary Immunodeficiencies link HIV infection , Down Syndrome others ) child know head/brain disease/injury Microcephaly , Macrocephaly others</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Days</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>